Systematic Review of Genotype-Phenotype Correlations in Frasier Syndrome

Yurika Tsuji1, Tomohiko Yamamura1, China Nagano1, Tomoko Horinouchi1, Nana Sakakibara1, Shinya Ishiko1, Yuya Aoto1, Rini Rossanti1, Eri Okada1, Eriko Tanaka2, Koji Tsugawa3, Takayuki Okamoto3, Toshihiro Sawai3, Yoshihori Araki3, Yuko Shima3, Koichi Nakanishi3, Hiroaki Nagase3, Masafumi Matsuo4, Kazumoto Iijima1 and Kandai Nozu1

1Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan; 2Department of Pediatrics, Kyorin University School of Medicine, Mitaka, Japan; 3Department of Pediatrics, Hiroaki University Hospital, Hiroaki, Japan; 4Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 5Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan; 6Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 7Department of Pediatrics, Wakayama Medical University, Wakayama, Japan; 8Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan; and 9Locomotion Biology Research Center, Kobe Gakuin University, Kobe, Japan

Introduction: Frasier syndrome (FS) is a rare inherited kidney disease caused by intron 9 splicing variants of WT1. For wild-type WT1, 2 active splice donor sites in intron 9 cause a mixture of 2 essential transcripts ([+KTS or –KTS]), and imbalance of the +KTS–KTS ratio results in the development of FS. To date, 6 causative intron 9 variants have been identified; however, detailed transcript analysis has not yet been conducted and the genotype-phenotype correlation also remains to be elucidated.

Methods: We conducted an in vitro minigene splicing assay for 6 reported causative variants and in vivo RNA sequencing to determine the +KTS–KTS ratio using patients’ samples. We also performed a systematic review of reported FS cases with a description of the renal phenotype.

Results: The in vitro assay revealed that although all mutant alleles produced –KTS transcripts only, the wild-type allele produced both +KTS and –KTS transcripts at a 1:1 ratio. In vivo RNA sequencing showed that patients’ samples with all heterozygous variants produced similar ratios of +KTS to –KTS (1.3:2–1.3:5) and wild-type kidney showed almost a 1:1 ratio (1:0.85). A systematic review of 126 cases clarified that the median age of developing ESKD was 16 years in all FS patients, and there were no statistically significant differences between the genotypes or sex chromosome karyotypes in terms of the renal survival period.

Conclusion: Our study suggested no differences in splicing pattern or renal survival period among reported intron 9 variants causative of FS.

KEYWORDS: genotype-phenotype correlation; Frasier syndrome; minigene assay; systematic review; transcript analysis

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Frasier syndrome is a rare inherited disease characterized by steroid-resistant nephrotic syndrome with proteinuria that begins in early childhood and progressively worsens with age. It is also associated with a high risk of developing ESKD, gonadal tumors, and male pseudohermodaphroditism (female external genitalia with XY sex chromosomes). It is caused by splice donor site variants in intron 9 of the Wilms’ tumor 1 (WT1 [NM_024426.6]) gene, with 6 variants identified thus far (c.1432+1 G>A, c.1432+2 T>C, c.1432+4 C>T, c.1432+5 G>A, c.1432+5 G>T, and c.1432+6 T>A). WT1 is composed of 10 exons and encodes a transcription factor with 4 zinc finger motifs; this transcription factor plays an important role in early gonadal and renal development by regulating the sex-determining region Y.

Two active splice donor sites of intron 9 result in a mixture of 2 transcripts with or without 3 amino acids (+KTS or –KTS) between zinc fingers 3 and 4. Although the roles of +KTS and –KTS isoforms have not yet been completely clarified, it has been
proposed that the −KTS isoform may function mostly as a transcriptional regulator, whereas the +KTS isoform acts predominantly at the posttranscriptional level. Furthermore, studies in animal models have also shown that these isoforms are essential for survival. Hammes et al. introduced the heterozygous variant into intron 9 of Wt1 in mice using a Cre-loxP strategy. These model mice showed a reduction of +KTS level and developed glomerulosclerosis, representing a model of FS. In contrast, the mice with homozygosity of this variant showed a complete lack of the +KTS isoform and died within 24 hours after birth due to kidney defects.

It is reported that the normal range of the WT1+/−KTS isoform ratio range is between approximately 5:2 and 1:1 (average 3:2), whereas intron 9 variants lead to a shift in this ratio to between 1:2 and 1:5 (average 1:2) in FS (Table 1), which indicates marked variability. However, all of these studies quantified the transcripts using a semiquantitative method based on agarose gel electrophoresis and need to be reexamined by quantitative analysis using RNA sequencing. Furthermore, in vitro assays on the role of intron 9 variants have been performed in 3 studies; however, these studies were limited to only 4 of the 6 known variants (c.1432+2T>C, c.1432+4C>T, c.1432+5G>A, and c.1432+5G>T).

Here, we conducted an in vitro splicing assay to measure the +/−KTS ratio for all reported intronic variants (c.1432+1G>A, c.1432+2T>C, c.1432+4C>T, c.1432+5G>A, c.1432+5G>T, and c.1432+6T>A) and a variant newly identified in our study (c.1432+3G>T). In addition, in vivo RNA sequencing using patients’ kidney-derived samples was conducted for 2 major variants (c.1432+4C>T, c.1432+5G>A) and a newly identified variant (c.1432+3G>T). Furthermore, we conducted a systematic review of previously reported cases of FS. With these analyses, we aimed to uncover genotype-phenotype correlations in FS and to determine differences in splicing pattern and clinical phenotype, mainly renal survival period, among the variants.

**METHODS**

**In Vitro Splicing Assay**

For in vitro splicing experiments, hybrid minigene constructs were created by inserting a test sequence comprising exon 9 of WTI and its flanking introns into a multiple cloning site within the intron between exons A and B of the minigene construct (H492) built into the pcDNA 3.0 mammalian expression vector (Thermo Fisher Scientific, Waltham, MA) as reported previously (Supplementary Figure S1). The test sequence was obtained by amplifying the control sample by polymerase chain reaction using primers that corresponded to introns 8 and 9 (Supplementary Table S1). These primers included NheI and BamHI restriction enzyme recognition sites, respectively. The amplified products were digested with NheI and BamHI (New England Biolabs, Ipswich, MA) and inserted into the minigene that had been digested with the same restriction enzymes. Furthermore, constructs containing each of the reported intronic variants were generated by mutagenesis (the primers used are listed in Supplementary Table S2).

Using this method, we constructed both wild-type and mutant hybrid minigenes that carried exon 9 and either the wild-type or a mutated (c.1432+1G>A, c.1432+2T>C, c.1432+3G>T, c.1432+4C>T, c.1432+5G>A, c.1432+5G>T, and c.1432+6T>A) intron 9 sequence. After the construct sequences had been confirmed by Sanger sequencing, the hybrid minigenes were transfected into HeLa and HEK293T cells with Lipofectamine 3000 (Thermo Fisher Scientific). These 2 cell types were chosen because both of them showed high efficiency for in vitro transfection and expressed sufficient levels of transfected mRNA in previous analysis for genes expressed predominantly in the kidney. Cells were harvested 24 hours after transfection, and total RNA was extracted with a RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). One microgram of total RNA was subjected to reverse transcription with the RNA to cDNA EcoDry Premix (Doubled Primed; Takara Bio, Otsu, Japan), and polymerase chain reaction was subsequently performed using a forward primer corresponding to a segment of the upstream exon A and a reverse primer.

**Table 1. +KTS/−KTS ratio determined by transcript analysis in previous studies and our targeted RNA sequencing**

| Variant | Tissue or cell | +KTS | −KTS | +KTS/−KTS ratio | Reference |
|---------|----------------|------|------|-----------------|-----------|
| c.1432+3G>T | Urine-derived cell | 383 | 1276 | 1:3.5 | — |
| c.1432+4C>T | Urine-derived cell | 136 | 430 | 1:3.2 | — |
| c.1432+5G>A | Kidney | 117 | 407 | 1:3.5 | — |
| Normal | Kidney | 213 | 181 | 1:0.85 | — |

+KTS, with lysine-threonine-serine; −KTS, without lysine-threonine-serine.
complementary to a segment of the downstream exon B as previously described. Polymerase chain reaction products were analyzed with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and direct sequencing (3130 Genetic Analyzer, Thermo Fisher Scientific).

In Vivo mRNA Analysis (Targeted RNA Sequencing)

To clarify the +KTS/−KTS mRNA ratio for in vivo samples, we analyzed patients’ samples for the most common variants (c.1432+4 C>T and c.1432+5 G>A). Furthermore, we analyzed the sample with the novel variant c.1432+3 G>T to confirm splicing abnormality. Total RNA was extracted from urine-derived cells (+3, +4) and kidney (+5) using the RNeasy Plus Mini Kit and ISOGEN RNA extraction reagent (Nippon Gene Co., Toyama, Japan), respectively. Samples of other variants were not available because of their rarity. We also obtained the wild-type kidney total RNA (Human Kidney Total RNA, #636529; Clontech Laboratories Inc., Mountain View, CA). A custom panel to detect WT1 was designed for the targeted RNA sequences. Targeted RNA sequencing samples were prepared using a SureSelect XT RNA Direct Reagent Kit (Agilent Technologies) in accordance with the manufacturer’s instructions. Amplified target libraries were then sequenced via MiSeq (Illumina, San Diego, CA). Trimmed and filtered reads were aligned to the human reference genome and transcriptome UCSC hg19 using Strand NGS 3.4 software (Strand Life Science Pvt. Ltd., Bangalore, India). +KTS/−KTS ratios were calculated from the average read depth in the last 9 bases of exon 9 for each +KTS/−KTS mRNA (Supplementary Figure S1).

Systematic Review

A systematic search of the PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/) was performed, and only those studies published in English and before December 2020 were included. The following search terms were used: “Frasier syndrome” or “Nephrotic syndrome AND WT1.” An additional search was conducted by selecting articles that included genotype and clinical data relevant to the current study, such as age of onset of nephrotic syndrome or ESKD, sex chromosomes, external genitalia, or tumor, from the reference sections of review articles. We constructed renal survival curves by Kaplan–Meier analysis to determine the prognosis and median age of onset of ESKD for each variant, and we determined that as the median age of onset of ESKD became younger, it increased in severity. Furthermore, we summarized the phenotype data reported for each variant including clinical descriptions relating to the external genitalia and sex chromosomes. In this study, patients were classified into the following 3 groups depending on their sex chromosome karyotype and the presence of disorder of sexual development (DSD): XX female (all patients with XX karyotype), XY female (XY karyotype with DSD), and XY male (XY karyotype without DSD). The definition of nephrotic syndrome in this study followed the description of each case report, and many of those reports did not include the detailed definition of nephrotic syndrome. Gonadal abnormality was defined as a mismatch between the sex of the chromosomes and the external genital phenotype.

Statistical Analysis

All calculations were performed using standard statistical software (JMP for Mac, version 14; SAS Institute, Cary, NC). The occurrence of events (renal survival period) was examined using the Kaplan-Meier and log-rank tests. Associations were considered to be statistically significant when P values were < 0.05.

RESULTS

In Vitro Splicing Assay

We conducted an in vitro splicing assay of wild-type and mutant minigene constructs to determine the splicing patterns resulting from the 6 intron 9 variants reported to date and a variant that we discovered (c.1432+3 G>T) associated with FS. Polymerase chain reaction products from the wild-type construct produced 2 bands following capillary electrophoresis (Figure 1a). Semiquantitative analysis with a bioanalyzer revealed that the molecular ratio of these 2 bands was approximately 1:1 (39.6 nmol/l:40.5 nmol/l). Sequencing of the amplicons from the wild-type construct indicated the presence of both +KTS and −KTS transcripts, whereas all mutant constructs produced only −KTS transcripts (Figure 1).

In Vivo mRNA Analysis

We conducted an in vivo mRNA analysis for 3 variants that were available for analysis: 2 variants from urine-derived cells (heterozygotes of 1432+3 G>T and c.1432 +4 C>T) and 1 from a kidney biopsy sample (heterozygote of c.1432 +5G>A), along with the wild-type kidney sample. The average depth of sequencing in the target region ranged from 394 to 1639 (Table 1). Our analysis revealed that the +KTS/−KTS ratio was 1.085 in a wild-type human kidney but 1:3.2 in c.1432+4 C>T and 1:3.5 in c.1432+3 G>T and c.1432+5 G>A (Table 1, Supplementary Figure S1). Although statistical analysis could not be conducted because only a single sample from each variant was available for analysis, all analyzed variants including
the newly detected variant c.1432+3 G>T showed almost the same +/− KTS ratio in RNA sequencing.

**Systematic Review**

Genetic and clinical data were obtained from a total of 126 cases: 115 cases described in previous reports and 11 cases diagnosed at our institution (Table 2). There were no significant differences in the proportions of patients with female external genitalia and XY chromosomes between the 2 major variants: c.1432+4 C>T (44/49, 90%) and c.1432+5 G>A (30/35, 86%) (Table 2, P = 0.57, χ² test). We could not conduct statistical analysis for the other variants because the sample numbers were too low. Regarding tumorigenesis, 1 and 31 cases had a Wilms tumor and a gonadal tumor, respectively. In addition, 14 cases had
undergone prophylactic gonadectomy. However, descriptions of a Wilms tumor or a gonadal tumor were only provided in 30 and 65 cases, respectively, so the prevalence of tumor in this study was calculated as 3.3% (1/30 cases) for a Wilms tumor and 61% (31/51 cases without prophylactic gonadectomy) for a gonadal tumor. We also analyzed the tumorigenesis for each sex chromosome karyotype and external genitalia (Supplementary Table S2). The results showed that 85% of patients who were XY female and none with XX chromosomes developed a gonadal tumor. Interestingly, 40% (2 in 5) of patients who were XY male developed a gonadal tumor, both of whom had been diagnosed with bilateral cryptorchidism.36,45

Regarding renal symptoms, among the 126 cases, there were descriptions of the age of onset of obvious proteinuria or nephrotic syndrome and kidney function for 102 and 116 cases, respectively. The results showed that the median age of onset of proteinuria was 4 years and that 58 cases had progressed to ESKD. We also created renal survival curves for all variants as well as individually for 2 major intronic variants (c.1432+4 C>T and c.1432+5 G>A) using Kaplan-Meier analysis (c.1432+1 G>A, n = 2; c.1432+2 T>C, n = 2; c.1432+3G>T, n = 1; c.1432+4 C>T, n = 61; c.1432+5 G>A, n = 47; c.1432+5 G>T, n = 2; and c.1432+6 T>A, n = 1) (Figure 2a and b). This analysis revealed that the median age of developing ESKD in the whole cohort was 16 years old. There was no significant difference between the 2 major variants c.1432+4 C>T (n = 61) and c.1432+5 G>A (n = 47) in the age of ESKD onset (17 vs. 15 years, P = 0.62, log-rank test; Figure 3a).

We divided the patients according to their sex chromosome karyotypes and analyzed the groups for differences in renal prognosis. No significant difference

| Table 2. Clinical descriptions of the external genitalia, sex chromosomes, renal manifestations, and gonadal/Wilms tumor |
|---------------------------------------------------------------|
| **WT1 mutations** | **N with data** | **Sex chromosomes and external genitalia** | **Renal manifestations** | **Gonadal tumor** | **Wilms tumor** |
|------------------|---------------|---------------------------------|-------------------------|----------------|----------------|
|                  |               | Median age of developing nephrotic syndrome (95% CI) | Median age of developing ESRD (95% CI) | Tumor detected | Prophylactic gonadectomy | Tumor detected |
| c.1432+1G>A      | 3             | 2 (n/c)                         | 7.5 (6–9)               | 1              | 0              | 0              |
| c.1432+2T>C      | 2             | 5.5 (5–6)                       | 23 (n/c)                | 0              | 0              | 0              |
| c.1432+3G>T      | 1             | 3 (n/c)                         | n/c                     | 0              | 0              | 0              |
| c.1432+4C>T      | 66            | 4 (3–5)                         | 17 (13–22)              | 19             | 8              | 1              |
| c.1432+5G>A      | 51            | 4 (2–5)                         | 15 (10–19)              | 11             | 4              | 0              |
| c.1432+5G>T      | 2             | 3 (n/c)                         | 25 (n/c)                | 0              | 1              | 0              |
| c.1432+6T>A      | 1             | 2 (n/c)                         | 35 (n/c)                | 0              | 1              | 0              |
| All              | 126           | 4 (3–5)                         | 16 (14–22)              | 31             | 14             | 1              |

CI, confidence interval; ESRD, end-stage renal disease.

*Sex chromosome karyotypes were not described in 3 cases of c.1432+4C>T and 1 case of c.1432+5G>A.

---

FIGURE 2. The renal survival rates associated with the intron 9 variants. (a) The renal survival curve for all variants (n = 116); the median age for the development of end-stage kidney disease (ESKD) was 16 years. (b) The renal survival curve for 2 major variants. The dashed line indicates patients with +4 C>T (n = 61); the median age for the development of ESKD was 17 years in these patients. The solid line indicates patients with +5 G>A (n = 47); the median age for the development of ESKD was 15 years in these patients. There was no significant difference between the 2 groups (P = 0.62, log-rank test).
in the age of ESKD onset was found between the patients with XX chromosomes \((n = 28)\) and XY chromosomes \((n = 84)\) \((29 \text{ vs.} 16 \text{ years}, P = 0.09, \text{log-rank test})\). In addition, to analyze whether the presence of DSD had any effect on renal prognosis, we classified the patients into the following 3 groups: group 1, XX \((n = 28)\); group 2, XY with DSD \((n = 74)\); and group 3, XY without DSD \((n = 10)\). However, there were no significant differences in the renal survival period among these groups (Figure 3b).

**DISCUSSION**

In this study, we conducted *in vitro* and *in vivo* assays for all reported and newly identified variants in intron 9 of *WT1* resulting in FS. In addition, we examined the genetic and clinical characteristics of reported patients with FS via a systematic review. Our results confirmed the presence of an abnormal splicing pattern in all variants both *in vitro* and *in vivo*. In addition, +KTS/–KTS mRNA ratios were equal for all variants evaluated in both analyses. Furthermore, a systematic review showed that there was no difference in renal prognosis according to genotype. Therefore, it was suggested that genotype does not affect renal prognosis in FS caused by *WT1* intron 9 variants.

In previous studies, transcript analysis was only performed for 4 of the intron 9 variants associated with FS: c.1432+2 T>C, c.1432+4 C>T, c.1432+5 G>A, and c.1432+5 G>T. These studies revealed that only the –KTS transcript is produced from mutant alleles, whereas both +KTS and –KTS transcripts are produced from the wild-type allele.\(^2,12\) Here, our *in vitro* assay revealed identical results for these 4 variants as well as for the other 2 rare variants (c.1432+1 G>A and c.1432+6 T>A) and a new variant (c.1432+3 G>T). Thus, it was confirmed that all intronic variants identified as being associated with FS to date disrupt the original splice donor site, resulting in production of only the –KTS transcript.

This study also focused on the production of +KTS/–KTS mRNA in renal tissue of the patients. Previous studies quantified the transcripts in patients by using a semiquantitative method based on agarose gel electrophoresis to determine the ratio of +KTS/–KTS transcripts, but the reported ratios show wide variation (Table 1). We quantified this ratio by RNA sequencing, revealing a +KTS/–KTS ratio of 1:0.85 in normal kidney and 1:3.2 to 3.5 in patients’ samples. Considering the ratio of +KTS/–KTS in a normal kidney, it was revealed that the +KTS transcript was not produced at equivalent levels for all analyzed variants. Although the performance of RNA sequencing for only 1 sample in each variant prevented us from examining the differences statistically, together with the *in vitro* assay, we concluded that all variants causing FS show the same splicing pattern.

In research on rare inherited diseases, large-scale clinical data on the disease including the genotype-
phenotype correlation are vitally important for both clinicians and patients to predict the clinical course or provide genetic counseling. To date, no large-scale investigations on the renal prognosis of patients with FS have been performed. As described in this report, a systematic literature review of 126 cases revealed that the median age of ESKD onset among FS patients is 16 years and that there is no significant difference in the median renal survival period between those with the 2 major WT1 variants in FS: c.1432+4 C>T and c.1432+5 G>A. This is compatible with our in vitro and in vivo mRNA study. All of these results led us to conclude that genotype does not influence renal prognosis in FS.

In a previous report, 65 cases of FS were summarized together with clinical descriptions of the patients’ external genitalia and sex chromosomes, and the ratios of patients with female external genitalia and XY chromosomes were calculated as 0.77 (17/22) for the c.1432+4 C>T variant and 0.93 (27/29) for the c.1432+5 G>A variant (P = 0.10, χ² test). Consistent with this, our meta-analysis of data from 83 patients showed no significant difference in the ratio of these patients between variants c.1432+4 C>T and c.1432+5 G>A (P = 0.66, χ² test).

Our study also focused on the influence of sex chromosome karyotypes and sexual development on renal prognosis. Sex differences in phenotype have been well established for various kidney diseases. In general, women are protected against renal diseases compared with men through estrogen’s inhibition and androgen’s activation of the renin-angiotensin system. Therefore, women show a lower risk of CKD progression than men. In addition, the renal prognosis in women with autosomal dominant polycystic kidney disease is better than that in men. However, women do not always have a lower incidence or severity of renal diseases; for example, women have been reported to have a higher risk of diabetic kidney disease. In this study, the median renal survival period tended to be longer in patients with a sex chromosome pattern of XX than in those with XY, although the difference was not statistically significant (29 vs. 16 years, P = 0.09, log-rank test). In addition, the renal prognosis in patients with XY chromosomes was not influenced by the presence of DSD (the median age of developing ESKD was 16 in DSD+ vs. 15 in DSD−, P = 0.84, log-rank test). Taking these findings together, differences in sex chromosome karyotypes and sexual development are not considered to influence the renal prognosis in FS.

Our study has some limitations. First, our analysis of the genotype-phenotype correlation is based on a retrospective systematic review. Thus, we could not collect clinical information regarding treatment or factors that might worsen renal function. Second, some of the reports that we analyzed in this study only focused on renal manifestations, with no detailed description of the sexual phenotype or tumorigenesis. The abnormalities of external genitalia seen in FS range from obvious discrepancies between the sex chromosome karyotypes and external genitalia to more subtle abnormalities. Therefore, the present study model may not be sufficient to clarify the correlation between renal genotype and the phenotype of sexual development in detail. However, we believe that our findings on the genotype and renal phenotype correlation in FS, which is the primary focus of this study, are important for clinicians, patients, and their families. We also conducted in vivo mRNA analysis only for urine-derived cell or kidney samples and not for other tissues such as gonads and blood samples. Therefore, we cannot assess the consistency of transcripts among different tissues. We also could not assess the difference in the +KTS/−KTS ratio between males and females. Finally, we did not conduct a sample size calculation because FS is a rare disease and we could only include all previous reported cases with sufficient clinical data. Therefore, the current results might have been affected by the small sample size.

In conclusion, we have confirmed that all variants, including the newly identified c.1432+3 G>T variant, result in the same abnormal splicing pattern as revealed by in vitro and in vivo transcript analyses. In addition, a large-scale meta-analysis suggested that renal prognosis was not influenced by the location of intron 9 variants, sex chromosomes karyotypes, or DSD. We believe that this study broadens our understanding of the genetic and clinical characteristics of FS.

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENTS

We thank Natasha Beeton-Kempen, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

This study was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Subject ID: 18K15713 to CN, 17H04189 to KI, and 19K08726 to K Nozu).

All procedures were reviewed and approved by the Institutional Review Board of Kobe University School of Medicine.
Y Tsuji et al.: Genotype-Phenotype Analysis in Frasier Syndrome

AUTHOR CONTRIBUTIONS
YT, TY, and KI designed the study and wrote the manuscript. K Nozu and TH interpreted the data and wrote the manuscript. CN, SI, YA, RR, EO, and NS collected and interpreted the data. ET, KT, TO, and TS collected urine and kidney samples for in vivo mRNA analysis. YS, K Naknishi, HN, and MM critically reviewed the manuscript. All authors read and approved the final version of the manuscript.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Figure S1. Comparison of the results of each patient in targeted RNA sequencing.
Table S1. Comparison of renal prognosis in patients with Frasier syndrome between different patterns of sex chromosomes and phenotypes of external genitalia.
Table S2. Prevalence of gonadal tumor in patients with Frasier syndrome depending on sex chromosomes karyotypes and phenotype of external genitalia.

REFERENCES
1. Miyoshi Y, Santo Y, Tachikawa K, et al. Lack of puberty despite elevated estradiol in a 46,XY phenotypic female with Frasier syndrome. Endocr J. 2006;53:371–376.
2. Kikuchi H, Takata A, Akasaka Y, et al. Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier syndrome? J Med Genet. 1998;35:45–48.
3. Barboux S, Niaudet P, Gubler MC, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet. 1997;17:467–470.
4. Klamt B, Koziel A, Poulat F, et al. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 ?/–KTS splice isoforms. Hum Mol Genet. 1998;7:709–714.
5. Schumacher V, Gueter B, Looijenga LH, et al. Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome. Mol Reprod Dev. 2008;75:1484–1494.
6. Hersmus R, van der Zwan YG, Stoop H, et al. A 46,XY female DSD patient with bilateral gonadoblastoma, a novel SRY missense mutation combined with a WT1 KTS splice-site mutation. PLoS One. 2012;7:e40858.
7. Haber DA, Sohn RL, Buckler AJ, et al. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A. 1991;88:9618–9622.
8. Davies RC, Calvio C, Bratt E, et al. WT1 interacts with the splicing factor U2AF65 in an isomeric-dependent manner and can be incorporated into spliceosomes. Genes Dev. 1998;12:3217–3225.
9. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription domains is regulated by alternative splicing. Cell. 1995;81:391–401.
10. Hammes A, Guo JK, Lutsch G, et al. Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 2001;106:319–329.
11. Denamur E, Bocquet N, Mougenot B, et al. Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases. J Am Soc Nephrol. 1999;10:2219–2223.
12. Bruening W, Bardeesy N, Silverman BL, et al. Germine intronic and exonic mutations in the Wilms’ tumour gene (WT1) affecting urogenital development. Nat Genet. 1992;1:144–148.
13. Nozu K, Iijima K, Kawai K, et al. In vivo and in vitro splicing assay of SLC12A1 in an antenatal salt-losing tubulopathy patient with an intronic mutation. Hum Genet. 2009;126:533–538.
14. Thi Tran HT, Takeshima Y, Surono A, et al. A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro. Mol Genet Metab. 2005;85:213–219.
15. Yamamura T, Nozu K, Miyoshi Y, et al. An in vitro splicing assay reveals the pathogenicity of a novel intronic variant in ATP6V0A4 for autosomal recessive distal renal tubular acidosis. BMC Nephrol. 2017;18:353.
16. Horinouchi T, Nozu K, Yamamura T, et al. Determination of the pathogenicity of known COL4A5 intronic variants by in vitro splicing assay. Sci Rep. 2019;9:12696.
17. Ahn YH, Park EJ, Kang HG, et al. Genotype-phenotype analysis of pediatric patients with WT1 glomerulopathy. Pediatr Nephrol. 2017;32:81–89.
18. Andrade JG, Guaragna MS, Soardi FC, et al. Clinical and genetic findings of five patients with WT1-related disorders. Arq Bras Endocrinol Metabol. 2008;52:1236–1243.
19. Bache M, Dheu C, Doray B, et al. Frasier syndrome, a potential cause of end-stage renal failure in childhood. Pediatr Nephrol. 2010;25:549–552.
20. Barbosa AS, Hadjiathanasiou CG, Theodoridis C, et al. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms’ tumor. Hum Mutat. 1999;13:146–153.
21. Bastian C, Muller JB, Lortat-Jacob S, et al. Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis. Fertil Steril. 2015;103:1297–1304.
22. Binczak-Kuleta A, Rubik J, Litwin M, et al. Retrospective mutational analysis of NPHS1, NPHS2, WT1 and LAMB2 in children with steroid-resistant focal segmental glomerulosclerosis - a single-centre experience. Bosn J Basic Med Sci. 2014;14:89–93.
23. Chan WK, To KF, But WM, et al. Frasier syndrome: a rare cause of delayed puberty. Hong Kong Med J. 2006;12:225–227.
24. Cheknev SB, Latsycheva OL, Denisov LA, et al. [Interactions of interferon with other immunomodulators in the regulation of human natural killer cell activity]. Biull Eksp Biol Med. 1992;113:179–182.
25. Cho HY, Lee JH, Choi HJ, et al. WT1 and NPHS2 mutations in Korean children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2008;23:63–70.
26. Demmer L, Primack W, Loik V, et al. Frasier syndrome: a cause of focal segmental glomerulosclerosis in a 46,XX female. J Am Soc Nephrol. 1999;10:2215–2218.
27. Denamur E, Bocquet N, Baudouin V, et al. WT1 splice-site mutations are rarely associated with primary steroid-resistant focal and segmental glomerulosclerosis. Kidney Int. 2000;57:1868–1872.
28. Ezaki J, Hashimoto K, Asano T, et al. Gonadal tumor in Frasier syndrome: a review and classification. Cancer Prev Res (Phila). 2015;8:271–276.
29. Frasier SD, Bashore RA, Mosier HD. Gonadoblastoma associated with pure gonadal dysgenesis in monozygous twins. J Pediatr. 1964;64:740–745.
30. Fujita S, Sugimoto K, Miyazawa T, et al. A female infant with Frasier syndrome showing splice site mutation in Wilms' tumor gene (WT1) intron 9. Clin Nephrol. 2010;73:487–491.
31. Gellermann J, Stefanidis CJ, Mitsioni A, et al. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol. 2010;25:1285–1289.
32. Ghiggeri GM, Aucella F, Caridi G, et al. Posttransplant recurrence of proteinuria in a case of focal segmental glomerulosclerosis associated with WT1 mutation. Am J Transplant. 2006;6:2208–2211.
33. Ismaili K, Pawtowski A, Boyer O, et al. Genetic forms of nephrotic syndrome: a single-center experience in Brussels. Pediatr Nephrol. 2009;24:287–294.
34. Ismaili K, Verdure V, Vandenhoucke K, et al. WT1 gene mutations in three girls with nephrotic syndrome. Eur J Pediatr. 2008;167:579–581.
35. Ito S, Hataya H, Ikeda M, et al. Alport syndrome-like basement membrane changes in Frasier syndrome: an electron microscopy study. Am J Kidney Dis. 2003;41:1110–1115.
36. Kitsiou-Tzeli S, Deligiorgi M, Malaktari-Skarantavou S, et al. Sertoli cell tumor and gonadoblastoma in an untreated 29-year-old 46,XY phenotypic male with Frasier syndrome carrying a WT1 IVS9+4C>T mutation. Hormones (Athens). 2012;11:361–367.
37. Koziell A, Charnandari E, Hindmarsh PC, et al. Frasier syndrome, part of the Denys Drash continuum or simply a WT1 gene associated disorder of intersex and nephropathy? Clin Endocrinol (Oxf). 2000;52:519–524.
38. Kumar AS, Sriakshmi R, Karthicheyan S, et al. Wilms' tumour 1 gene mutations in south Indian children with steroid-resistant nephrotic syndrome. Indian J Med Res. 2016;144:276–280.
39. Li J, Ding J, Zhao D, et al. WT1 gene mutations in Chinese children with early onset nephrotic syndrome. Pediatr Res. 2010;68:155–158.
40. Lipska BS, Iatropoulos P, Maranta R, et al. Genetic screening in adolescents with steroid-resistant nephrotic syndrome. Kidney Int. 2013;84:206–213.
41. Lowik M, Levchenko E, Westra D, et al. Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2008;23:3146–3151.
42. Maesaka A, Higuchi A, Kotoh S, et al. Gonadal function in 15 patients associated with WT1 gene mutations. Clin Pediatr Endocrinol. 2006;15:143–149.
43. Matsumoto F, Shimada K, Ida S. Tumors of bilateral streak gonads in patients with disorders of sex development containing Y chromosome material. Clin Pediatr Endocrinol. 2014;23:93–97.
44. Megremis S, Mitsioni A, Fylaktou I, et al. Broad and unexpected phenotypic expression in Greek children with steroid-resistant nephrotic syndrome due to mutations in the Wilms' tumor 1 (WT1) gene. Eur J Pediatr. 2011;170:1529–1534.
45. Melo KF, Martin RM, Costa EM, et al. An unusual phenotype of Frasier syndrome due to IVS9 +4C>T mutation in the WT1 gene: predominantly male ambiguous genitalia and absence of gonadal dysgenesis. J Clin Endocrinol Metab. 2002;87:2500–2505.
46. Mestrallet G, Bertholet-Thomas A, Ranchin B, et al. Recurrence of a dysgerminoma in Frasier syndrome. Pediatr Transplant. 2011;15:e53–55.
47. Nso Roca AP, Pena Carrion A, Benito Gutierrez M, et al. Evolutive study of children with diffuse mesangial sclerosis. Pediatr Nephrol. 2009;24:1013–1019.
48. Okuhara K, Tajima S, Nakae J, et al. A Japanese case with Frasier syndrome caused by the splice junction mutation of WT1 gene. Endocr J. 1999;46:639–642.
49. Peco-Antic A, Ozaltin F, Parezanovic V, et al. Proteinuria in Frasier syndrome. Srp Arh Celok Lek. 2013;141:685–688.
50. Ruf RG, Schultheiss M, Lichtenberger A, et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int. 2004;66:564–570.
51. Shimoyma H, Nakajima M, Naka H, et al. A girl with bilateral ovarian tumours: Frasier syndrome. Eur J Pediatr. 2002;161:81–83.
52. Sinha A, Sharma S, Gulati A, et al. Frasier syndrome: early gonadoblastoma and cyclosporine responsiveness. Pediatr Nephrol. 2010;25:2171–2174.
53. Subbiah V, Huff V, Wolff JE, et al. Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1-IVS9 mutation: a 46 XY phenotypic female with Frasier syndrome. Pediatr Blood Cancer. 2009;53:1349–1351.
54. Tajima T, Sasaki S, Tanaka Y, et al. 46,XY phenotypic male with focal segmental glomerulosclerosis caused by the WT1 splice site mutation. Horm Res. 2003;60:302–305.
55. Tan W, Lovric S, Ashraf S, et al. Analysis of 24 genes reveals a monogenic cause in 11.1% of cases with steroid-resistant nephrotic syndrome at a single center. Pediatr Nephrol. 2018;33:305–314.
56. Wang F, Zhang Y, Mao J, et al. Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2017;32:1181–1192.
57. Wong YS, Tam YH, Pang KKY, et al. Clinical heterogeneity in children with gonadal dysgenesis associated with nonmosaic 46,XY karyotype. Pediatr Urol. 2017;13:508.e–508.e6.
58. Yang YH, Zhao F, Feng DN, et al. Wilms' tumor suppressor gene mutations in girls with sporadic isolated steroid-resistant nephrotic syndrome. Genet Mol Res. 2013;12:6184–6191.
59. Kang AK, Miller JA. Impact of gender on renal disease: the role of the renin angiotensin system. Clin Invest Med. 2003;26:3844.
60. Ricardo AC, Yang W, Sha D, et al. Sex-related disparities in CKD progression. J Am Soc Nephrol. 2019;30:137–146.
61. Cornez-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24:1006–1013.
62. Yu MK, Lyles CR, Bent-Shaw LA, et al. Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study. Am J Nephrol. 2012;36:245–251.